Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

Inclusion Criteria: * Adult ≥18 years old * Patient diagnosed with Stage IV NSCLC (de novo or earlier stage progression to stage IV) * Absence of oncogene activating mutations eligible patients to targeted therapy (EGFR, ALK) * Cohort A: Received first line treatment with pembrolizumab monotherapy * Cohort B: Received first line treatment with chemotherapy and pembrolizumab combination therapy * Cohort C: Received first line treatment with chemotherapy doublet Exclusion Criteria: * Prior anti-cancer therapy for actual stage IV NSCLC * Critical data missing (e.g., PD-L1 status, baseline millimetric imaging, first evaluation millimetric imaging) * Patients participating in other clinical trials that modify the standard of care